INmune Bio Inc. announced the receipt of approximately $4.2 million in research and development cash rebates from Australia on July 30, 2026. This follows a separate rebate of approximately $0.4 million received from the United Kingdom in June 2026, bringing total non-dilutive proceeds to roughly $4.6 million. The company states that these funds strengthen its balance sheet and extend its cash runway without requiring additional equity issuance. INmune Bio is a late-stage biotechnology company focused on developing treatments targeting the innate immune system for inflammation and immunology.
